PLANO, Texas--(BUSINESS WIRE)-- #Biotech--Secretome Therapeutics, a clinical-stage biotechnology company developing novel therapies derived from neonatal cardiac progenitor cells (nCPC), today announced the closing of a $30 million Series A financing from RA Capital Management, LP (“RA Capital”), a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital was the sole investor in the financing.